Department of Urology, Hôpital Huriez, Lille University Hospital, Lille, France.
Eur Urol. 2011 Nov;60(5):1055-65. doi: 10.1016/j.eururo.2011.07.062. Epub 2011 Aug 4.
Adrenocortical carcinoma (ACC) is a rare and typically aggressive malignancy. Available recommendations are based primarily on retrospective series or expert opinions, and only few prospective clinical studies have yet been published.
To combine the available evidence for diagnostic work-up and treatment of ACC to a contemporary recommendation on the management of this disease.
We conducted a systematic literature search for studies conducted on humans and published in English using the Medline/PubMed database up to 31 January 2011. In addition, we screened published abstracts at meetings and several Web sites for recommendations on ACC management.
In patients with suspected localised ACC, a thorough endocrine and imaging work-up is followed by complete (R0) resection of the tumour by an expert surgeon. In experienced hands, laparoscopic adrenalectomy is probably as effective and safe for localised and noninvasive ACC as open surgery. Most clinicians agree that mitotane should be used as adjuvant therapy in the majority of patients, as they have a high risk for recurrence. An international panel has suggested using tumour stage, resection status, and the proliferation marker Ki67 as guidance for or against adjuvant therapy. In patients with advanced disease at presentation or recurrence not amenable to complete resection, a surgical approach is frequently inadequate. In these cases, mitotane alone or in combination with cytotoxic drugs is the treatment of choice. The most promising regimens (etoposide, doxorubicin, cisplatin plus mitotane, and streptozotocin plus mitotane) are currently compared in an international phase 3 trial, and results should be available by the end of 2011. Several targeted therapies are under investigation and may lead to new treatment options. Management of endocrine manifestations with steroidogenesis inhibitors is required in patients suffering uncontrolled hormone excess.
Detailed recommendations are provided to guide the management of patients with ACC.
肾上腺皮质癌(ACC)是一种罕见且通常具有侵袭性的恶性肿瘤。现有的推荐意见主要基于回顾性研究系列或专家意见,仅有少数前瞻性临床研究发表。
将目前关于 ACC 诊断和治疗的证据综合起来,形成对这种疾病管理的当代推荐意见。
我们使用 Medline/PubMed 数据库系统地检索了截至 2011 年 1 月 31 日发表的以人类为对象、用英文撰写的研究。此外,我们还筛选了会议发表的摘要和若干网站上关于 ACC 管理的推荐意见。
对于疑似局限性 ACC 的患者,在进行全面的内分泌和影像学检查后,由专家外科医生进行肿瘤的完全(R0)切除。在有经验的外科医生手中,腹腔镜肾上腺切除术对于局限性和非侵袭性 ACC 与开放手术同样有效和安全。大多数临床医生认为,对于大多数患者,由于其复发风险较高,米托坦应该作为辅助治疗。一个国际专家组建议使用肿瘤分期、切除状态和增殖标志物 Ki67 作为辅助治疗的指导。对于在初始阶段或无法完全切除的复发时处于晚期的患者,手术方法往往不充分。在这些情况下,米托坦单独或与细胞毒药物联合应用是治疗的首选。最有希望的方案(依托泊苷、多柔比星、顺铂加米托坦、链脲佐菌素加米托坦)目前正在一项国际 3 期临床试验中进行比较,结果预计在 2011 年底公布。目前正在研究几种靶向治疗方法,可能会带来新的治疗选择。对于患有激素过量且无法控制的患者,需要使用类固醇生成抑制剂来治疗内分泌表现。
提供了详细的建议来指导 ACC 患者的管理。